ReviewCurrent allergy and asthma reports2021
Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.
Review in Current allergy and asthma reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Comparison of rapid and same-day desensitization protocols in hypersensitivity reactions to platinum and taxanes: a retrospective cohort study.Frontiers in allergy · 2026Article
- Recent Insights into the Epidemiology and Management of AnaphylaxisBalkan medical journal · 2025Review
- Combination Gadolinium Angiography and Intravascular Ultrasound Study for Coronary Artery and Graft Assessment.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Knowledge mapping and global trends of drug hypersensitivity from 2013 to 2023: A bibliometric analysis.Immunity, inflammation and disease · 2024Article
- Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations.The World Allergy Organization journal · 2024Article
- Immune Reactions in Major Types of Oncological Treatment.International journal of molecular sciences · 2023Review
- Inflammation Control and Tumor Growth Inhibition of Ovarian Cancer by Targeting Adhesion Molecules of E-Selectin.Cancers · 2023Article
- Utilizing Biologics in Drug Desensitization.Current allergy and asthma reports · 2023Review
- Desensitization for the prevention of drug hypersensitivity reactions.The Korean journal of internal medicine · 2022Review
- Review
- How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?Frontiers in immunology · 2021Review
- Use of Rapid Drug Desensitization in Delayed Hypersensitivity Reactions to Chemotherapy and Monoclonal Antibodies.Frontiers in allergy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions (HSRs) to antineoplastic drugs are increasing due to the expanding use of classical and new drugs in a wide variety of malignancies. PURPOSE OF REVIEW: The goal of this review is to provide current best practices in the diagnosis and management of HSRs based on data and evidence. RECENT
findingsA plethora of studies have provided evidence of the safety and efficacy of rapid drug desensitizations (RDD) to allow for the reintroduction of antineoplastic drugs following an HSR, based on risk stratification. Recently described biomarkers such as basophil activation test, total IgE, BRCA genotyping, and serum IL-6 can aid in guiding improved precision desensitization protocols. Personalized premedication regimens and protocols have improved RDD safety and outcomes. RDD allows for the continued use of chemotherapeutic drugs without impaired drug efficacy. RDD represents the best approach to maintain cancer patients on their most effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.